Quick Answer
Coherus Oncology, Inc. reported Total Revenue of $0.00 for fiscal year 2018.
Coherus Oncology, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | — | — | — | — | — | — |
| Net Income | $168.02M +489.4% |
$28.51M +112.0% |
-$237.89M +18.5% |
-$291.75M -1.6% |
-$287.10M -317.1% |
$132.24M +47.2% |
| Diluted EPS | $1.43 +472.0% |
$0.25 +109.9% |
-$2.53 +32.7% |
-$3.76 +1.3% |
-$3.81 -335.2% |
$1.62 +31.7% |
| Total Assets | $258.34M -42.4% |
$448.53M -28.8% |
$629.60M +30.9% |
$480.85M -29.2% |
$679.33M -19.3% |
$841.65M +105.8% |
| Cash and Equivalents | $88.88M -29.5% |
$125.99M +22.4% |
$102.89M +61.9% |
$63.55M -84.8% |
$417.19M -22.9% |
$541.16M +204.6% |
| Stockholders Equity | $61.01M +146.2% |
-$131.99M +31.8% |
-$193.43M -40.8% |
-$137.42M -240.6% |
$97.73M -65.2% |
$280.97M +167.1% |
| R&D Expense | $108.89M +18.6% |
$91.83M -16.1% |
$109.44M -45.1% |
$199.36M -45.1% |
$363.11M +154.3% |
$142.76M +51.6% |
| Operating Income | -$181.13M +9.3% |
-$199.65M +1.7% |
-$203.20M +20.9% |
-$256.88M +2.6% |
-$263.86M -268.8% |
$156.32M +45.1% |
| Shares Outstanding | 121.15M +4.8% |
115.61M +3.0% |
112.22M +42.3% |
78.85M +2.5% |
76.93M +6.1% |
72.51M +3.1% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | June 30, 2017 | $1.40M | -90.0% | -90.0% |
| Revenue (ASC 606) | June 30, 2017 | $1.40M | — | — |
| Net Income | September 30, 2025 | -$35.53M | -230.5% | -111.9% |
| Diluted EPS | September 30, 2025 | -$0.31 | -244.4% | -112.1% |
| Total Assets | September 30, 2025 | $516.52M | +2.3% | +17.5% |
| Cash and Equivalents | September 30, 2025 | $103.35M | +5.8% | -52.3% |
| Long-Term Debt | June 30, 2019 | $73.29M | — | +0.2% |
| Stockholders Equity | September 30, 2025 | $87.77M | +199.8% | -26.7% |
| R&D Expense | September 30, 2025 | $27.25M | +23.6% | +3.6% |
| Operating Income | September 30, 2025 | -$44.33M | +5.4% | +2.5% |
| Shares Outstanding | September 30, 2025 | 116.24M | +0.9% | +0.0% |
- Coherus Oncology, Inc. reported Total Revenue of $0.00 for fiscal year 2018.
- Coherus Oncology, Inc. showed a decrease of -100.0% in Total Revenue compared to the prior fiscal year.
- Coherus Oncology, Inc. reported Net Income of $168.02 million for fiscal year 2025.
- Coherus Oncology, Inc. showed an increase of +489.4% in Net Income compared to the prior fiscal year.
- Coherus Oncology, Inc. reported Diluted EPS of $1.43 per share for fiscal year 2025.
- Coherus Oncology, Inc. showed an increase of +472.0% in Diluted EPS compared to the prior fiscal year.
- Coherus Oncology, Inc. reported Total Assets of $258.34 million for fiscal year 2025.
- Coherus Oncology, Inc. showed a decrease of -42.4% in Total Assets compared to the prior fiscal year.
- Coherus Oncology, Inc. reported Cash and Equivalents of $88.88 million for fiscal year 2025.
- Coherus Oncology, Inc. showed a decrease of -29.5% in Cash and Equivalents compared to the prior fiscal year.
- Coherus Oncology, Inc. reported Stockholders Equity of $61.01 million for fiscal year 2025.
- Coherus Oncology, Inc. showed an increase of +146.2% in Stockholders Equity compared to the prior fiscal year.
- Coherus Oncology, Inc. reported R&D Expense of $108.89 million for fiscal year 2025.
- Coherus Oncology, Inc. showed an increase of +18.6% in R&D Expense compared to the prior fiscal year.
- Coherus Oncology, Inc. reported Operating Income of -$181.13 million for fiscal year 2025.
- Coherus Oncology, Inc. showed an increase of +9.3% in Operating Income compared to the prior fiscal year.
- Coherus Oncology, Inc. reported Shares Outstanding of 121.15 million shares for fiscal year 2025.
- Coherus Oncology, Inc. showed an increase of +4.8% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: